448 related articles for article (PubMed ID: 21428727)
1. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.
Barzilai N; Guo H; Mahoney EM; Caporossi S; Golm GT; Langdon RB; Williams-Herman D; Kaufman KD; Amatruda JM; Goldstein BJ; Steinberg H
Curr Med Res Opin; 2011 May; 27(5):1049-58. PubMed ID: 21428727
[TBL] [Abstract][Full Text] [Related]
2. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes.
Hanefeld M; Herman GA; Wu M; Mickel C; Sanchez M; Stein PP;
Curr Med Res Opin; 2007 Jun; 23(6):1329-39. PubMed ID: 17559733
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study.
Williams-Herman D; Johnson J; Teng R; Luo E; Davies MJ; Kaufman KD; Goldstein BJ; Amatruda JM
Curr Med Res Opin; 2009 Mar; 25(3):569-83. PubMed ID: 19232032
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes.
Aschner P; Katzeff HL; Guo H; Sunga S; Williams-Herman D; Kaufman KD; Goldstein BJ;
Diabetes Obes Metab; 2010 Mar; 12(3):252-61. PubMed ID: 20070351
[TBL] [Abstract][Full Text] [Related]
6. Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus.
Iwamoto Y; Taniguchi T; Nonaka K; Okamoto T; Okuyama K; Arjona Ferreira JC; Amatruda J
Endocr J; 2010; 57(5):383-94. PubMed ID: 20332588
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials.
Signorovitch JE; Wu EQ; Swallow E; Kantor E; Fan L; Gruenberger JB
Clin Drug Investig; 2011; 31(9):665-74. PubMed ID: 21819162
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial.
Arechavaleta R; Seck T; Chen Y; Krobot KJ; O'Neill EA; Duran L; Kaufman KD; Williams-Herman D; Goldstein BJ
Diabetes Obes Metab; 2011 Feb; 13(2):160-8. PubMed ID: 21199268
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes.
Nonaka K; Kakikawa T; Sato A; Okuyama K; Fujimoto G; Kato N; Suzuki H; Hirayama Y; Ahmed T; Davies MJ; Stein PP
Diabetes Res Clin Pract; 2008 Feb; 79(2):291-8. PubMed ID: 17933414
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.
Nauck MA; Meininger G; Sheng D; Terranella L; Stein PP;
Diabetes Obes Metab; 2007 Mar; 9(2):194-205. PubMed ID: 17300595
[TBL] [Abstract][Full Text] [Related]
11. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.
Aschner P; Kipnes MS; Lunceford JK; Sanchez M; Mickel C; Williams-Herman DE;
Diabetes Care; 2006 Dec; 29(12):2632-7. PubMed ID: 17130196
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
Bergenstal RM; Wysham C; Macconell L; Malloy J; Walsh B; Yan P; Wilhelm K; Malone J; Porter LE;
Lancet; 2010 Aug; 376(9739):431-9. PubMed ID: 20580422
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
14. Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA(1c) value.
Krobot KJ; Ferrante SA; Davies MJ; Seck T; Meininger GE; Williams-Herman D; Kaufman KD; Goldstein BJ
Curr Med Res Opin; 2012 Aug; 28(8):1281-7. PubMed ID: 22697277
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes.
Raz I; Chen Y; Wu M; Hussain S; Kaufman KD; Amatruda JM; Langdon RB; Stein PP; Alba M
Curr Med Res Opin; 2008 Feb; 24(2):537-50. PubMed ID: 18194595
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study.
Yoon KH; Steinberg H; Teng R; Golm GT; Lee M; O'Neill EA; Kaufman KD; Goldstein BJ
Diabetes Obes Metab; 2012 Aug; 14(8):745-52. PubMed ID: 22405352
[TBL] [Abstract][Full Text] [Related]
17. A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with type 2 diabetes experiencing inadequate glycaemic control on metformin and sitagliptin.
Violante R; Oliveira JH; Yoon KH; Reed VA; Yu MB; Bachmann OP; Lüdemann J; Chan JY
Diabet Med; 2012 Nov; 29(11):e417-24. PubMed ID: 22375612
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes.
Scott R; Loeys T; Davies MJ; Engel SS;
Diabetes Obes Metab; 2008 Sep; 10(10):959-69. PubMed ID: 18201203
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency.
Chan JC; Scott R; Arjona Ferreira JC; Sheng D; Gonzalez E; Davies MJ; Stein PP; Kaufman KD; Amatruda JM; Williams-Herman D
Diabetes Obes Metab; 2008 Jul; 10(7):545-55. PubMed ID: 18518892
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
Lavalle-González FJ; Januszewicz A; Davidson J; Tong C; Qiu R; Canovatchel W; Meininger G
Diabetologia; 2013 Dec; 56(12):2582-92. PubMed ID: 24026211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
